← back to search

Wolf Roesler

Friedrich-Alexander-Universität Erlangen-Nürnberg · DE
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Medicine, Internal medicine, Graft-versus-host disease, Biomarker, Transplantation, and Hematopoietic stem cell transplantation.
h-index
citations
32
works
12
NIH funding
primary concept
email

Recent publications

Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
Blood Advances 2023cited by 10position: middledoi
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Frontiers in Immunology 2023cited by 7position: middledoi
Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
Blood 2022cited by 0position: middledoi
Prognostic Value of Elafin in Acute Graft-Versus-Host Disease
Blood 2021cited by 0position: middledoi
Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease
Blood 2018cited by 0position: middledoi
An Early Biomarker Algorithm Predicts Lethal Graft-Vs-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation 2017cited by 0position: middledoi
Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment
Biology of Blood and Marrow Transplantation 2017cited by 0position: middledoi
Differences Between CEBPA bZIP and TAD Mutations and Their Effect on Outcome-an Analysis in 4578 Patients with Acute Myeloid Leukemia
Blood 2016cited by 8position: middledoi
An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation
Blood 2016cited by 1position: middledoi
Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment
Blood 2016cited by 0position: middledoi
Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma
Blood 2014cited by 4position: middledoi
Lenalidomide, Adriamycin and Dexamethasone (RAD) As An Induction Regimen In Newly Diagnosed Multiple Myeloma – Interim Results From a German Multicenter Phase II Trial
Blood 2013cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sabrina Kraus · University of Würzburg2 papers (2013–2023) · 2 papers (2013–2016)Hermann Einsele · Ovarian Cancer Research Alliance2 papers (2013–2016) · 1 papers (2023–2023)Wolfgang E. Berdel · Klinik für Schlafmedizin1 papers (2016–2016)Markus Weber · University of Regensburg1 papers (2023–2023)Christoph Röllig · Hopp Children's Cancer Center Heidelberg1 papers (2013–2013)Stefan Knop · City of Hope1 papers (2013–2013)Evelyn Ullrich · Goethe University Frankfurt1 papers (2023–2023)Franziska Taube · Hochschule für Technik und Wirtschaft Dresden – University of Applied Sciences1 papers (2016–2016)Peter Bader · Children's Clinical University Hospital1 papers (2023–2023)Ralf C. Bargou · Comprehensive Cancer Center Mainfranken1 papers (2013–2013)Sigrun Gleich · University of Regensburg1 papers (2023–2023)Matthias Eder · German Cancer Research Center1 papers (2023–2023)Ernst Holler · Polyclinic Medical Center1 papers (2023–2023)Claudia D. Baldus · Universitätsklinikum Knappschaftskrankenhaus Bochum1 papers (2016–2016)Daniel Wolff · Polyclinic Medical Center1 papers (2023–2023)Jan Moritz Middeke · Digital Health Cooperative Research Centre1 papers (2016–2016)Elisabeth Meedt · University of Regensburg1 papers (2023–2023)Albrecht Reichle · University Hospital Regensburg1 papers (2013–2013)